DelveInsight has launched a new report on “Community-acquired Bacterial Pneumonia (CABP) – Market Insights, Epidemiology, and Market Forecast-2030
DelveInsight’s “Community-acquired Bacterial Pneumonia (CABP) – Market Insights, Epidemiology, and Market Forecast-2030″ report deliver an in-depth understanding of the Community-acquired Bacterial Pneumonia (CABP), historical and forecasted epidemiology as well as the Community-acquired Bacterial Pneumonia (CABP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Report:
-
A prospective population-based cohort study estimated that approximately 5.6 million cases of CAP were reported annually in the United States with an annual age-adjusted incidence of 649 patients hospitalized with CAP/100,000 adults, which corresponded to 1,591,825 annual adult CAP hospitalizations during the study period from 2014 to 2016.
-
According to the book, approximately 3,370,000 cases of CAP are reported annually in the European Union with 1 million hospitalizations. Furthermore, the adult incidence of CAP in Europe ranges from 1.7–11.6 cases/1,000 people/year
-
As per a study, there were approximately 1.9 million new CAP cases that occurred every year in Japan with nearly 70% of cases being reported in the >65 age group.
Key benefits of the report:
1. Community-acquired Bacterial Pneumonia (CABP) market report covers a descriptive overview and comprehensive insight of the Community-acquired Bacterial Pneumonia (CABP) epidemiology and Community-acquired Bacterial Pneumonia (CABP) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Community-acquired Bacterial Pneumonia (CABP) market report provides insights on the current and emerging therapies.
3. Community-acquired Bacterial Pneumonia (CABP) market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Community-acquired Bacterial Pneumonia (CABP) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Community-acquired Bacterial Pneumonia (CABP) market.
Request for sample pages: https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-market
Community-acquired Bacterial Pneumonia (CABP): Overview
Community-acquired bacterial pneumonia (CABP) is a common, acute, severe infection of the lung parenchyma. It is a major cause of mortality in adults in Asia. It is one of the most frequent respiratory illnesses among various infections triggering sepsis.
The key players involved in Community-acquired Bacterial Pneumonia (CABP) market:
-
Paratek Pharmaceuticals
-
Melinta Therapeutics
The launch of the emerging therapies is expected to significantly impact the Community-acquired Bacterial Pneumonia (CABP) treatment scenario in the upcoming years:-
Drug covered
-
Nuzyra
-
Baxdela
Request a free sample report @https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-market
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Community-acquired Bacterial Pneumonia (CABP) Patient Share (%) Overview at a Glance
5. Community-acquired Bacterial Pneumonia (CABP) Market Overview at a Glance
6. Community-acquired Bacterial Pneumonia (CABP) Disease Background and Overview
7. Community-acquired Bacterial Pneumonia (CABP) Epidemiology and Patient Population
8. Country-Specific Patient Population of Community-acquired Bacterial Pneumonia (CABP)
9. Community-acquired Bacterial Pneumonia (CABP) Current Treatment and Medical Practices
10. Unmet Needs
11. Community-acquired Bacterial Pneumonia (CABP) Emerging Therapies
12. Community-acquired Bacterial Pneumonia (CABP) Market Outlook
13. Country-Wise Community-acquired Bacterial Pneumonia (CABP) Market Analysis (2017–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Community-acquired Bacterial Pneumonia (CABP) Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Community-acquired Bacterial Pneumonia (CABP)- Pipeline Insights, 2021
“Community-acquired Bacterial Pneumonia (CABP) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Community-acquired Bacterial Pneumonia (CABP) market. A detailed picture of the Community-acquired Bacterial Pneumonia (CABP) pipeline landscape is provided, which includes the disease overview and Community-acquired Bacterial Pneumonia (CABP) treatment guidelines.
Community-acquired Bacterial Pneumonia (CABP) – Epidemiology Forecast to 2030
DelveInsight’s ‘Community-acquired Bacterial Pneumonia (CABP) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Community-acquired Bacterial Pneumonia (CABP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/